Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 15.81% |
| A M R CP | AAMRQ | 8.48% |
| JAZZ PHARMAC | JAZZ | 7.12% |
| SANTARUS INC | SNTS | 5.87% |
| DIXIE GROUP | DXYN | 4.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The stock market has erased most of the early summer losses and is now within striking distance of the spring high. While the gains earlier on were concentrated largely in defensive and counter cyclical stocks, the momentum seems to have broadened a bit following the Friday jobs report. But the gains lack in conviction, as the small caps have lagged the large-caps -- likely a reflection that the market remains ambivalent about the economic and Fed policy outlook.
We will not get any clarity on those fronts given the dearth of economic reports this week. But the clamor for more Fed support does not seem to have died down following the July jobs report as indicated by the Boston Fed President’s interview with the Wall Street Journal, where he advocates for an open-ended new round of bond purchases by the central bank.
Eric Rosengren, the Boston Fed chief, does not have a vote on the FOMC, but his policy stance is a reflection of others like New York President Bill Dudley and Fed vice chairwoman Janet Yellen, who do have votes.
We will get more clarity over this debate within the FOMC later this month at the Fed’s annual Jackson Hole huddle. Bernanke had used the Jackson Hole platform in 2010 to telegraph his QE2 plans in 2011. We will have another monthly jobs report and a host of other economic indicators before the Fed’s next scheduled meeting on September 12 and 13th.
The Fed aside, we are in the last stretch of second quarter reporting season, with Disney ( DIS - Analyst Report ) and Priceline ( ( PCLN - Analyst Report ) on tap to report results after the close today.
Of this morning’s basket of results, CVS Caremark’s ( ( CVS - Analyst Report ) report incorporated the two key elements that we have seen repeatedly this earnings season – two thirds of the companies have beaten earnings expectations, but more than 60% have fallen short on the revenue side. In fairness to CVS, however, the drug store chain guided higher while many others have done the opposite. Beer maker Molson Coors ( ( TAP - Analyst Report ) beat earnings and revenue expectations this morning.
Read the full Analyst Report on PCLN
Read the full Analyst Report on DIS
Read the full Analyst Report on CVS
Read the full Analyst Report on TAP